MENLO PARK, Calif.--(BUSINESS WIRE)--
Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of
Single Molecule Real Time (SMRT®) sequencing products, today
announced the appointment of Michael J. Glynn as Chief Commercial
Officer.
Michael Glynn has more than 40 years of experience in global commercial
operations. Prior to joining Pacific Biosciences, Mr. Glynn served as
Regional President, Japan - Asia Pacific and Senior Vice President at
Genzyme Corporation. In this role, he was responsible for leading and
managing Genzyme's businesses in Japan and Asia Pacific from the
company's regional headquarters in Singapore.
Prior to joining Genzyme in January 2007, Mr. Glynn was with Boston
Scientific for seven years, most recently as President of its
Endovations division in the United States, and prior to that as Vice
President and General Manager, Asia, Middle East, and Turkey. From
1995-2000 he was President and CEO of Codman Group, a developer of
healthcare decision support software and home telemedicine systems
(formerly Caremonitor, Inc.). He also spent seven years with Memtec
Limited as President of Memtec Japan and President of Memtec America.
Before joining Memtec he spent ten years with Baxter International in
Australia and the United States where he held a variety of management
positions in manufacturing, quality assurance, marketing, and strategic
planning. Earlier in his career Mr. Glynn held a variety of
manufacturing and technical management positions with companies in
Australia and England, including Burroughs Wellcome, Estee Lauder, and
Elizabeth Arden. He holds an M.B.A. from Macquarie University in Sydney
and a B.S. from the National University of Ireland.
"Michael has exceptional commercial experience with an emphasis on
customer satisfaction and support for industry-leading companies
operating in global markets," said Hugh Martin, Chairman and Chief
Executive Officer of Pacific Biosciences. "He has excellent capabilities
to lead the next phase of our commercialization strategy for the PacBio RS,
and his deep experience with clinical products will be
extremely important as next generation sequencing moves closer to
patient care."
In this new position, Mr. Glynn will oversee the day-to-day management
of Pacific Biosciences' commercial operations, including all field
sales, support and marketing activities.
"As someone who has lived and worked on four continents I am thrilled to
be joining the exceptional team at Pacific Biosciences as the company
ramps up its commitment to providing commercial operations around the
world," said Mr. Glynn. "PacBio's recently introduced, game-changing
technology has already shown the tremendous impact it can have in public
health applications such as pathogen detection. I look forward to
helping the company build a world-class commercial operation that will
create further value for our customers."
For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.
You can also follow the company on twitter www.twitter.com/pacbio.
About Pacific Biosciences
Pacific Biosciences' mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT®,
technology. SMRT technology enables real-time analysis of biomolecules
with single molecule resolution, which has the potential to transform
the understanding of biological systems by providing a window into these
systems that has not previously been open for scientific study.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements may contain words such as "believe," "may," "estimate,"
"anticipate," "continue," "intend," "expect," "plan," the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company's SMRT technology. These
statements are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements, including but not limited to risks discussed
from time to time in documents Pacific Biosciences of California, Inc.
has filed with the Securities and Exchange Commission, including the
risks identified under the section captioned "Risk Factors" in its
recently filed Quarterly Report on Form 10-Q. All forward-looking
statements are based on estimates, projections and assumptions as of the
date hereof. Pacific Biosciences undertakes no obligation to update any
forward-looking statements.
For Pacific Biosciences
Nicole Litchfield, 415-793-6468 (Media)
nicole@bioscribe.com
or
Pacific
Biosciences
Trevin Rard, 650-521-8450 (Investors)
ir@pacificbiosciences.com
Source: Pacific Biosciences of California, Inc.
News Provided by Acquire Media